NasdaqGS:GILDBiotechs
Gilead’s Arcellx Deal Deepens Oncology Focus And Reshapes Investor Risk Profile
Gilead Sciences (NasdaqGS:GILD) agreed to acquire Arcellx in a US$7.8b deal.
The transaction gives Gilead full rights to anito cel, a CAR T cell therapy for multiple myeloma.
Anito cel has received fast track status and is being positioned as a next generation option in blood cancer treatment.
For you as an investor, this move extends Gilead beyond its established antiviral and cell therapy work into a deeper role in hematologic oncology. Multiple myeloma is an area with significant...